沉默TRIM8可以缓解过敏性喘,并通过抑制NF-κB/NLRP3信号通路来抑制Th2分化

相关实验视频

Updated: Jun 13, 2025

06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

1.6K

Yao Tang¹, Yan Zhao², Yuanyuan Guan²

¹Department of Allergy, The First Affiliated Hospital of Harbin Medical University, Harbin, PR China; Department of Internal Medicine, Harbin Medical University, Harbin, PR China; NHC Key Laboratory of Cell Transplantation, Harbin, PR China.

Immunology letters

|September 11, 2024

概括

含有8 (TRIM8) 蛋白质的沉默三方基因通过抑制Th2细胞发育和炎症,减少了小鼠的过敏喘症状. 这一发现强调了TRIM8作为过敏性喘的潜在治疗标.

科学领域:

免疫学免疫学免疫学
分子生物学分子生物学
呼吸系统医学呼吸系统医学

背景情况:

过敏性喘的特征是T助手2 (Th2) 细胞介导的炎症.
三方基因含有8 (TRIM8) 蛋白在过敏性喘中的作用尚不清楚.
发现TRIM8表达在卵蛋白 (OVA) 挑战小鼠的肺部升高.

研究的目的:

研究TRIM8对过敏性喘发展的影响.
阐明TRIM8在Th2细胞分化和相关信号通路中的作用.

主要方法:

在小鼠中使用OVA挑战诱导过敏性喘.
在喘模型小鼠中,TRIM8使用通过鼻腔吸入输送的腺病毒载体被击败.
分析了Th2细胞的百分比,Th2细胞因子水平 (IL-4,IL-5,IL-13) 和NF-κB/NLRP3信号通路.

主要成果:

在喘小鼠肺部和Th2诱导的CD4+细胞中,TRIM8的表达很高.
在体内和体外,TRIM8 knockdown显著抑制了OVA诱导的Th2细胞发育和细胞因子分泌.
TRIM8通过阻断TAK1来抑制NF-κB/NLRP3通路,NLRP3过度表达反转了这一效应.

结论:

沉默TRIM8通过抑制NF-κB/NLRP3通路缓解了喘症状和Th2发育.
在过敏性喘中,TRIM8通过NF-κB/NLRP3信号通路促进呼吸道炎症.
TRIM8代表了一种针对过敏性喘治疗的新型潜在治疗标.

关键词:

过敏性喘是一种过敏性喘.在 NF-κBB 中.在NLRP3中,NLRP3是NLRP3中的一个.在 TRIM8 中,Th2分化的差异化

相关概念视频

01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

246

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

246

01:20

Asthma: Pathogenesis and Management

371

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

371

01:17

Drugs Used in Lower Respiratory Disorders: Overview

362

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

362

01:26

Asthma-II: Pathophysiology and Classification

2.6K

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

2.6K

01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

228

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Allergic Reactions